NEW PROGRAM - A Team Approach to Supportive Oncodermatology ~ .50 ANCC CESocial Media CoordinatorOct 20, 20211 min readClick the image to learn more!
CAR-Therapy Adverse Reaction Identification and Management Considerations ~ Thursday, June 12th @ Davio's
NEW EVENT: Exploring the Role of NUBEQA (darolutamide) in mHSPC in Combination with Docetaxel and in nmCRPC PP-NUM-US-3389-1
Comments